Targets › HRH3
2 programs from 2 companies in 5 trials: 4 Phase 3, 1 Phase 2; Neurology, Other, Psychiatry; next expected readout Apr 2027.
The H3 subclass of histamine receptors could mediate the histamine signals in CNS and peripheral nervous system. Signals through the inhibition of adenylate cyclase and displays high constitutive activity (spontaneous activity in the absence of agonist). (UniProt, Q9Y5N1)
Open in Phaseline: the race on HRH3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Harmony Biosciences Management | Pitolisant (HBS-301) Histamine H3 receptor inverse agonist | HRH3 | Phase 3 | Prader-Willi Syndrome; Idiopathic Hypersomnia; EDS; Autism Spectrum Disorder | Apr 2027 |
| Suven Life Sciences | Suvn-G3031 Histamine H3 receptor inverse agonist | HRH3 | Phase 3 | Narcolepsy | Nov 2027 |
Prader-Willi Syndrome (1) Idiopathic Hypersomnia (1) EDS (1) Autism Spectrum Disorder (1) Narcolepsy (1)
protein or peptide (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.